Zydus Lifesciences Ltd.
Snapshot View

View in App

Prices View details >>

432.60 -3.00 ▼-0.7%

02 February 2023, 04:01:00 PM
Volume: 31,287

Overview View Details >>

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.zyduscadila.com
Market Cap 43,787.95 Cr.
Enterprise Value(EV) 45,422.85 Cr. 2022-09
Financial Indicators
Earnings per share (EPS) 19.15 Trailing Twelve Months Ending 2022-09
Price-Earning Ratio (PE) 22.59 Trailing Twelve Months Ending 2022-09
Industry PE 32.44 Trailing Twelve Months Ending 2022-09
Book Value / Share 164.64 Trailing Twelve Months Ending 2022-09
Price to Book Value 2.63 Calculated using Price: 432.60
Dividend Yield 0.58 Period Ending 2022-03
No. of Shares Subscribed 101.22 Cr. 1,012,204,139 Shares
FaceValue 1
Company Profile
The company is one of the leading innovation driven pharmaceutical companies in India with presence across the pharmaceutical value chain of innovating (research & development), manufacturing, marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, including biosimilars and vaccines), active pharmaceutical ingredients (APIs), animal healthcare products and consumer wellness products. Innovation is the backbone of the company as it ensures business sustainability through continuous availability of new products for various businesses.

Delivery View Details >>

Delivered Qty
Traded Qty

Performance View Details >>

1 Day
-0.69%
1 Week
+1.53%
1 Month
+3.11%
3 Month
-0.92%
6 Month
+23.51%
1 Year
+4.37%
2 Year
-7.45%
5 Year
+5.64%
10 Year
+152.27%

Ratios View Details >>

9 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03 2021-03 2022-03
Return on Equity (%) 26.20 30.85 38.62 23.43 22.26 19.36 11.32 18.88 15.51
Return on Capital Employed (%) 17.67 23.21 28.60 16.50 18.41 15.89 10.02 14.23 15.30
Return on Assets (%) 10.89 13.93 20.14 12.18 11.11 9.34 5.18 9.66 9.40

Balance Sheet View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09* Rs. Cr.
Shh. Funds 3,439 4,252 5,699 6,960 8,745 10,386 10,376 12,992 17,000 16,665
Non Curr. Liab. 1,589 1,342 736 1,903 2,122 3,491 2,854 19 -194 -426
Curr. Liab. 2,814 3,285 3,461 5,306 6,083 7,343 8,269 7,861 7,839 6,121
Minority Int. 144 169 136 156 191 1,293 1,335 1,937 2,054 2,103
Equity & Liab. 7,987 9,047 10,032 14,325 17,141 22,513 22,834 22,810 26,700 24,463
Non Curr. Assets 4,549 4,820 5,752 8,303 8,911 14,015 14,118 14,094 14,438 14,751
Curr. Assets 3,438 4,227 4,280 6,022 8,230 8,498 8,715 8,716 12,261 9,712
Misc. Exp. not W/O
Total Assets 7,987 9,047 10,032 14,325 17,141 22,513 22,834 22,810 26,700 24,463

Profit Loss View Details >>

Particulars 10 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr. 2022-09 Rs. Cr. TTM
Net Sales 7,224 8,651 9,427 9,377 11,955 13,166 14,253 14,404 15,265 15,726
Other Income 86 57 117 147 133 209 117 47 235 250
Total Income 7,310 8,709 9,543 9,524 12,088 13,374 14,370 14,451 15,501 15,976
Total Expenditure -6,031 -6,897 -7,097 -7,475 -9,126 -10,187 -11,473 -11,018 -11,935 -12,608
PBIDT 1,279 1,811 2,446 2,049 2,962 3,187 2,897 3,433 3,565 3,369
Interest -118 -68 -53 -63 -111 -196 -342 -159 -127 -139
Depreciation -201 -287 -292 -373 -539 -599 -697 -670 -713 -731
Taxation -106 -259 -177 -129 -564 -530 -320 -194 -512 -475
Exceptional Items -17 -10 -3 0 -10 -364 -205 113 -3
PAT 836 1,186 1,921 1,483 1,748 1,852 1,176 2,206 2,326 2,020
Minority Interest -33 -38 -30 -29 -35 -50 -28 -51 -131 -128
Share Associate 43 34 63 47 29 47 46 64
Other Related Items
Consolidated Net Profit 804 1,151 1,934 1,488 1,776 1,849 1,177 2,134 4,487 1,939
Adjusted EPS 8 11 19 15 17 18 11 21 44 19

Cash Flow View Details >>

Particulars 10 years 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr. 2021-03 Rs. Cr. 2022-03 Rs. Cr.
Cash Fr. Operatn. 603 903 994 1,894 1,312 919 1,282 2,932 3,294 2,104
Cash Fr. Inv. -682 -438 -465 -864 -2,872 -974 -4,239 -1,012 -725 1,154
Cash Fr. Finan. 286 -529 -351 -935 2,316 52 1,885 -1,528 -2,548 -868
Net Change 207 -64 178 95 756 -3 -1,072 391 22 2,390
Cash & Cash Eqvt 677 613 790 837 1,593 1,590 779 1,178 1,087 3,460

Shareholding Pattern View Details >>

9 Qtrs 2020-12 (%) 2021-03 (%) 2021-06 (%) 2021-09 (%) 2021-12 (%) 2022-03 (%) 2022-06 (%) 2022-09 (%) 2022-12 (%)
Promoter 74.88 74.88 74.88 74.88 74.88 74.88 74.88 74.98 74.98
Public 25.12 25.12 25.12 25.12 25.12 25.12 25.12 25.02 25.02
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details >>

Mon, 30 Jan 2023
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Q3 FY23 post results earning call details
Fri, 27 Jan 2023
Announcement under Regulation 30 (LODR)-Press Release / Media Release
We wish to inform that the USFDA conducted an inspection at the manufacturing facility of Zydus Lifesciences Limited located at Moraiya Ahmedabad from 23rd to 27th January 2023. Theinspection was a Pre-Approval Inspection (PAI) for Transdermal Patch products. The inspection concluded with NIL observations.
Mon, 23 Jan 2023
Board Meeting Intimation for Approval Of Unaudited Financial Results
Zydus Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2023 inter alia to consider and approve unaudited financial results for the quarter / nine months ended on December 31 2022.

Technical Scans View Details >>

Thu, 02 Feb 2023
Higher Delivery Quantity Higher Delivery Quantity
Close Within 52 Week High Zone Close Within 52 Week High Zone
High Increase in 6 Months High Increase in 6 Months
Wed, 01 Feb 2023
Close Crossing Last Month Close From Below Close Crossing Last Month Close From Below
Closing Above Previous High Closing Above Previous High

Related Stocks View Details >>

  • SALES
Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 241,852.96 1,008.00 -0.6%
Divi's Laboratories Ltd. 86,732.57 3,271.90 -2.5%
Cipla Ltd. 82,728.22 1,024.95 -0.7%
Dr. Reddy's Laboratories Ltd. 72,771.66 4,366.00 +0.4%
Apollo Hospitals Enterprise Ltd. 60,864.05 4,234.95 -0.8%
Torrent Pharmaceuticals Ltd. 52,144.29 1,541.15 +0.5%
Abbott India Ltd. 43,527.39 20,505.50 -0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 57.42 1,008.00 -0.6%
Divi's Laboratories Ltd. Consolidated 2022-09 29.03 3,271.90 -2.5%
Cipla Ltd. Consolidated 2022-12 31.36 1,024.95 -0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 19.95 4,366.00 +0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 72.52 4,234.95 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 62.77 1,541.15 +0.5%
Abbott India Ltd. Standalone 2022-09 49.36 20,505.50 -0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-12 4.37 1,008.00 -0.6%
Divi's Laboratories Ltd. Consolidated 2022-09 7.16 3,271.90 -2.5%
Cipla Ltd. Consolidated 2022-12 3.65 1,024.95 -0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-12 3.30 4,366.00 +0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-09 10.17 4,234.95 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-12 8.18 1,541.15 +0.5%
Abbott India Ltd. Standalone 2022-09 16.04 20,505.50 -0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 0.03 1,008.00 -0.6%
Divi's Laboratories Ltd. Consolidated 2022-03 0.00 3,271.90 -2.5%
Cipla Ltd. Consolidated 2022-03 0.04 1,024.95 -0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 0.18 4,366.00 +0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 0.47 4,234.95 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 0.68 1,541.15 +0.5%
Abbott India Ltd. Standalone 2022-03 0.00 20,505.50 -0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,008.00 -0.6%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,271.90 -2.5%
Cipla Ltd. Consolidated 2022-03 13.10 1,024.95 -0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,366.00 +0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,234.95 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,541.15 +0.5%
Abbott India Ltd. Standalone 2022-03 29.95 20,505.50 -0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 7.21 1,008.00 -0.6%
Divi's Laboratories Ltd. Consolidated 2022-03 28.16 3,271.90 -2.5%
Cipla Ltd. Consolidated 2022-03 13.10 1,024.95 -0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 11.55 4,366.00 +0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 21.60 4,234.95 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 13.18 1,541.15 +0.5%
Abbott India Ltd. Standalone 2022-03 29.95 20,505.50 -0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 38,654.49 1,008.00 -0.6%
Divi's Laboratories Ltd. Consolidated 2022-03 8,959.83 3,271.90 -2.5%
Cipla Ltd. Consolidated 2022-03 21,763.34 1,024.95 -0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 21,545.20 4,366.00 +0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 14,662.60 4,234.95 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 8,508.04 1,541.15 +0.5%
Abbott India Ltd. Standalone 2022-03 4,919.27 20,505.50 -0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2022-03 3,405.82 1,008.00 -0.6%
Divi's Laboratories Ltd. Consolidated 2022-03 2,960.45 3,271.90 -2.5%
Cipla Ltd. Consolidated 2022-03 2,559.47 1,024.95 -0.7%
Dr. Reddy's Laboratories Ltd. Consolidated 2022-03 2,112.20 4,366.00 +0.4%
Apollo Hospitals Enterprise Ltd. Consolidated 2022-03 1,101.10 4,234.95 -0.8%
Torrent Pharmaceuticals Ltd. Consolidated 2022-03 777.18 1,541.15 +0.5%
Abbott India Ltd. Standalone 2022-03 798.70 20,505.50 -0.9%

FAQ's On Zydus Lifesciences Ltd.

What is Zydus Lifesciences share price?
Can I buy Zydus Lifesciences shares now?
What is the Dividend Yield of Zydus Lifesciences?
What is the Market Cap of Zydus Lifesciences?
What are the key metrics to analyse Zydus Lifesciences?
What is the 52 Week High and Low of Zydus Lifesciences?
What is the trend of Zydus Lifesciences share price?